Jeffrey Frelick
Recent Quotes
"We reiterate our Buy rating on QDEL, as increased flu activity will support the new Sofia immunoassay platform launch."
—
Jeffrey Frelick, Canaccord Genuity
(12/2/12)
more >
"We are certain QDEL can drive $100M of new product revenues by 2014."
—
Jeffrey Frelick, Canaccord Genuity
(4/25/12)
more >
"We have confidence in QDEL's growth prospects."
—
Jeffrey Frelick, Canaccord Genuity
(3/25/12)
more >
Due to permission requirements, not all quotes are shown.
